Article
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2018
Zhang Gao, Wu Lawrence W, Mender Ilgen, Barzily-Rokni Michal, Hammond Marc R, Ope Omotayo, Cheng Chaoran, Vasilopoulos Themistoklis, Randell Sergio, Sadek Norah, Beroard Aurelie, Xiao Min, Tian Tian, Tan Jiufeng, Saeed Umar, Sugarman Eric, Krepler Clemens, Brafford Patricia, Sproesser Katrin, Murugan Sengottuvelan, Somasundaram Rajasekharan, Garman Bradley, Wubbenhorst Bradley, Woo Jonathan, Yin Xiangfan, Liu Qin, Frederick Dennie T, Miao Benchun, Xu Wei, Karakousis Giorgos C, Xu Xiaowei, Schuchter Lynn M, Mitchell Tara C, Kwong Lawrence N, Amaravadi Ravi K, Lu Yiling, Boland Genevieve M, Wei Zhi, Nathanson Katherine, Herbig Utz, Mills Gordon B, Flaherty Keith T, Herlyn Meenhard, Shay Jerry W
Abstract excerpt
Purpose: Telomerase promoter mutations are highly prevalent in human tumors including melanoma. A subset of patients with metastatic melanoma often fail multiple therapies, and there is an unmet and urgent need to prolong disease control for those patients.Experimental Design: Numerous preclinical therapy-resistant models of human and mouse melanoma were used to test the efficacy of a telomerase-directed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.